Patents by Inventor Yunfu Luo
Yunfu Luo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10239838Abstract: The present invention is directed to heteroaryl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.Type: GrantFiled: December 14, 2015Date of Patent: March 26, 2019Assignee: Merck Sharp & Dohme Corp.Inventors: Scott D. Kuduk, Nigel Liverton, Yunfu Luo
-
Patent number: 10227336Abstract: The present invention is directed to pyrazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the pyrazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.Type: GrantFiled: October 27, 2015Date of Patent: March 12, 2019Assignee: Merck Sharp & Dohme CorpInventors: Nigel Liverton, Scott D. Kuduk, Yunfu Luo
-
Patent number: 10214535Abstract: The present invention is directed to hydroxymethyl piperidine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.Type: GrantFiled: November 30, 2015Date of Patent: February 26, 2019Assignee: Merck Sharp & Dohme Corp.Inventors: Scott D. Kuduk, Nigel Liverton, Yunfu Luo
-
Patent number: 10189831Abstract: Compounds of Formula I: are HIV reverse transcriptase inhibitors, wherein R1, R2, RE, L, M and Z are defined herein. The compounds of Formula I and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.Type: GrantFiled: June 7, 2017Date of Patent: January 29, 2019Assignee: Merck Sharp & Dohme Corp.Inventors: Kenneth L. Arrington, Yongxin Han, Yaozong Li, Yunfu Luo, Mehul Patel
-
Publication number: 20180370973Abstract: The present invention is directed to fused heteroaryl derivative compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.Type: ApplicationFiled: December 18, 2015Publication date: December 27, 2018Applicant: Merck Sharp & Dohme Corp.Inventors: Scott D. Kuduk, Nigel Liverton, Douglas C. Beshore, Na Meng, Yunfu Luo
-
Patent number: 10155750Abstract: The present invention is directed to amidoethyl azole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.Type: GrantFiled: December 18, 2015Date of Patent: December 18, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Scott D. Kuduk, Nigel Liverton, Yunfu Luo
-
Patent number: 10150751Abstract: The present invention is directed to pyrrolidine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.Type: GrantFiled: December 14, 2015Date of Patent: December 11, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Scott D. Kuduk, Nigel Liverton, Yunfu Luo, Jason W. Skudlarek
-
Patent number: 10017507Abstract: Disclosed are a series of diaza-benzofluoranthrene compounds. The present invention particularly relates to a compound represented by formula (I), pharmaceutically acceptable salts or tautomers thereof.Type: GrantFiled: February 2, 2016Date of Patent: July 10, 2018Assignee: HARBIN PHARMACEUTICAL GROUP CO., LTD. GENERAL PHARMACEUTICAL FACTORYInventors: Shujie Yuan, Xinchun Yang, Jinlong Zhao, Daoxu Zhang, Mingda Sun, Jiaji Liu, Tao Wei, Huanan Zhao, Yunfu Luo, Chundao Yang
-
Patent number: 10017504Abstract: The present invention is directed to piperidine isoxazole and isothiazole orexin compounds which are antagonists of orexin receptors. Such compounds are of the general structural formula I: wherein the variables are defined herein. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the prevention or treatment of such diseases in which orexin receptors are involved.Type: GrantFiled: October 27, 2015Date of Patent: July 10, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Nigel Liverton, Scott D. Kuduk, Douglas Beshore, Yunfu Luo, Na Meng, Tingting Yu
-
Patent number: 10010539Abstract: The present invention is directed to pyrazole, triazole and tetrazole compounds which are antagonists of orexin receptors. Such compounds are of the general structural formula I: The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.Type: GrantFiled: October 27, 2015Date of Patent: July 3, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Nigel Liverton, Scott D. Kuduk, Douglas Beshore, Yunfu Luo, Na Meng
-
Patent number: 9981969Abstract: The present invention relates to Imidazole Derivatives of Formula (I), and pharmaceutically acceptable salts thereof, wherein A, B, Y, R1 and R2 are as defined herein. The present invention also relates to compositions comprising at least one Imidazole Derivative, and methods of using the Imidazole Derivatives for inhibiting CYP450 3A. Inhibition of CYP450 3A can be used to improve the pharmacokinetics of a drug that is metabolized by CYP450 3A4.Type: GrantFiled: June 2, 2014Date of Patent: May 29, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Craig A. Coburn, Milana Maletic, Yunfu Luo, Zhiqi Qi, Chunsing Li, Tingting Yu, Richard Soll
-
Patent number: 9975888Abstract: The present invention relates to aryl linked imidazole and triazole derivatives, compositions comprising said compounds, alone or in combination with other drugs, and methods of using the compounds for improving the pharmacokinetics of a drug. The compounds of the invention are useful in human and veterinary medicine for inhibiting CYP3A4 and for improving the pharmacokinetics of a therapeutic compound that is metabolized by CYP3A4.Type: GrantFiled: November 7, 2014Date of Patent: May 22, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Craig A. Coburn, Milana M. Maletic, Yunfu Luo, Zhiqi Qi, Chun Sing Li, Tingting Yu
-
Publication number: 20180104220Abstract: Disclosed is an imidazole compound, in particular, the compound as shown in formula (I) and a pharmaceutically acceptable salt or tautomer thereof are disclosed.Type: ApplicationFiled: April 22, 2016Publication date: April 19, 2018Inventors: Shuhui CHEN, Yunfu LUO, Jianfeng PAN
-
Patent number: 9920038Abstract: The present invention is directed to methyloxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.Type: GrantFiled: November 30, 2015Date of Patent: March 20, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Scott D. Kuduk, Nigel Liverton, Yunfu Luo
-
Publication number: 20180016270Abstract: Disclosed are a series of diaza-benzofluoranthrene compounds. The present invention particularly relates to a compound represented by formula (I), pharmaceutically acceptable salts or tautomers thereof.Type: ApplicationFiled: February 2, 2016Publication date: January 18, 2018Inventors: Shujie Yuan, Xinchun Yang, Jinlong Zhao, Daoxu Zhang, Mingda Sun, Jiaji Liu, Tao Wei, Huanan Zhao, Yunfu Luo, Chundao Yang
-
Publication number: 20170349585Abstract: Compounds of Formula I: are HIV reverse transcriptase inhibitors, wherein R1, R2, RE, L, M and Z are defined herein. The compounds of Formula I and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.Type: ApplicationFiled: June 7, 2017Publication date: December 7, 2017Applicant: Merck Sharp & Dohme Corp.Inventors: Kenneth L. Arrington, Christopher Burgey, Robert Gilfillan, Yongxin Han, Chun Sing Li, Yaozong Li, Yunfu Luo, Zhiyu Lei
-
Publication number: 20170342052Abstract: The present invention is directed to pyrrolidine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.Type: ApplicationFiled: December 14, 2015Publication date: November 30, 2017Applicant: Merck Sharp & Dohme Corp.Inventors: Scott D. Kuduk, Nigel Liverton, Yunfu Luo, Jason W. Skudlarek
-
Patent number: 9828368Abstract: The present invention is directed to oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the oxazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.Type: GrantFiled: August 4, 2014Date of Patent: November 28, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Nigel Liverton, Douglas C. Beshore, Scott D. Kuduk, Yunfu Luo, Na Meng, Tingting Yu
-
Publication number: 20170327490Abstract: The present invention is directed to piperidine isoxazole and isothiazole orexin compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the prevention or treatment of such diseases in which orexin receptors are involved.Type: ApplicationFiled: October 27, 2015Publication date: November 16, 2017Applicant: MERCK SHARP & DOHME CORP.Inventors: NIGEL LIVERTON, SCOTT D. KUDUK, DOUGLAS BESHORE, YUNFU LUO, NA MENG, TINGTING XU
-
Publication number: 20170319560Abstract: The present invention is directed to pyrazole, triazole and tetrazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the pyrazole, triazole, and tetrazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.Type: ApplicationFiled: October 27, 2015Publication date: November 9, 2017Applicant: MERCK SHARP & DOHME CORP.Inventors: NIGEL LIVERTON, SCOTT D. KUDUK, DOUGLAS BESHORE, YUNFU LUO, NA MENG